Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) Net Margin (2020 - 2025)

Historic Net Margin for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q2 2025 value amounting to 2112600.0%.

  • Barinthus Biotherapeutics' Net Margin changed N/A to 2112600.0% in Q2 2025 from the same period last year, while for Sep 2025 it was 23957.73%, marking a year-over-year decrease of 235710500.0%. This contributed to the annual value of 408.73% for FY2024, which is 87492500.0% up from last year.
  • Latest data reveals that Barinthus Biotherapeutics reported Net Margin of 2112600.0% as of Q2 2025.
  • Over the past 5 years, Barinthus Biotherapeutics' Net Margin peaked at 1683700.0% during Q4 2021, and registered a low of 2112600.0% during Q2 2025.
  • Its 5-year average for Net Margin is 40586.32%, with a median of 3893.8% in 2023.
  • As far as peak fluctuations go, Barinthus Biotherapeutics' Net Margin skyrocketed by 2000000000bps in 2021, and later plummeted by 2000000000bps in 2022.
  • Quarter analysis of 5 years shows Barinthus Biotherapeutics' Net Margin stood at 1683700.0% in 2021, then tumbled by -100bps to 327.75% in 2022, then crashed by -2076bps to 7132.93% in 2023, then surged by 99bps to 54.31% in 2024, then crashed by -3890109bps to 2112600.0% in 2025.
  • Its Net Margin was 2112600.0% in Q2 2025, compared to 6220.89% in Q1 2025 and 54.31% in Q3 2024.